New fixed-duration therapy could reshape CLL care

By 2025-05-28T09:00:10

Abstract,Vertical,Illustration,Of,Targeting,Cancer,Cell,Made,Of,Glowing

Advancements in chronic lymphocytic leukaemia (CLL) treatment, like the AMPLIFY Phase III trial combining acalabrutinib and venetoclax, offer less toxic and more effective options. Learn from AstraZeneca’s Benjamin Moutier about how this breakthrough highlights the potential of targeted therapies to improve outcomes and reduce treatment burden, marking a key moment ...

Already a member? Sign in

Unlock

Intelligence for the future of drug discovery

By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member